<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>mRNA vaccine technology &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/mrna-vaccine-technology/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 05 Nov 2025 19:20:48 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>mRNA vaccine technology &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>MIT Study Identifies Promising Targets for Next-Generation Tuberculosis Vaccine</title>
		<link>https://bioengineer.org/mit-study-identifies-promising-targets-for-next-generation-tuberculosis-vaccine/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 05 Nov 2025 19:20:30 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Immunopeptidomics]]></category>
		<category><![CDATA[MHC class II antigens]]></category>
		<category><![CDATA[mRNA vaccine technology]]></category>
		<category><![CDATA[Mycobacterium tuberculosis antigens]]></category>
		<category><![CDATA[Tuberculosis vaccine development]]></category>
		<guid isPermaLink="false">https://bioengineer.org/mit-study-identifies-promising-targets-for-next-generation-tuberculosis-vaccine/</guid>

					<description><![CDATA[In a groundbreaking advance that could redefine tuberculosis (TB) vaccine development, researchers at the Massachusetts Institute of Technology have identified promising antigenic targets from Mycobacterium tuberculosis, the bacterium responsible for the world’s deadliest infectious disease. Utilizing cutting-edge immunopeptidomics, the team screened over 4,000 proteins to pinpoint specific peptides capable of provoking robust immune responses. This [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">292131</post-id>	</item>
		<item>
		<title>Breakthrough Discovery: Novel Vaccine Target Identified to Halt Malaria Transmission</title>
		<link>https://bioengineer.org/breakthrough-discovery-novel-vaccine-target-identified-to-halt-malaria-transmission/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 07 Aug 2025 01:46:46 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[cryo-electron microscopy]]></category>
		<category><![CDATA[Malaria vaccine development]]></category>
		<category><![CDATA[mRNA vaccine technology]]></category>
		<category><![CDATA[Plasmodium falciparum protein structure]]></category>
		<category><![CDATA[Transmission-blocking vaccines]]></category>
		<guid isPermaLink="false">https://bioengineer.org/breakthrough-discovery-novel-vaccine-target-identified-to-halt-malaria-transmission/</guid>

					<description><![CDATA[Australian scientists at the Walter and Eliza Hall Institute (WEHI) have made a groundbreaking discovery in the fight against malaria by visualizing, for the first time, the intricate structure of a crucial protein complex that enables the malaria parasite to reproduce within mosquitoes. This achievement, enabled by advanced cryo-electron microscopy (cryo-EM) techniques, has paved the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">254198</post-id>	</item>
		<item>
		<title>COVID-19 vaccine generates immune structures critical for lasting immunity</title>
		<link>https://bioengineer.org/covid-19-vaccine-generates-immune-structures-critical-for-lasting-immunity/</link>
					<comments>https://bioengineer.org/covid-19-vaccine-generates-immune-structures-critical-for-lasting-immunity/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 28 Jun 2021 20:00:21 +0000</pubDate>
				<category><![CDATA[Immunology]]></category>
		<category><![CDATA[antibody persistence]]></category>
		<category><![CDATA[COVID-19 vaccine]]></category>
		<category><![CDATA[germinal centers]]></category>
		<category><![CDATA[immune response]]></category>
		<category><![CDATA[Infectious/Emerging Diseases]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<category><![CDATA[mRNA vaccine technology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/covid-19-vaccine-generates-immune-structures-critical-for-lasting-immunity/</guid>

					<description><![CDATA[Vaccines likely induce strong, persistent immunity to COVID-19 The first two COVID-19 vaccines authorized for emergency use by the Food and Drug Administration (FDA) employed a technology that had never before been used in FDA-approved vaccines. Both vaccines performed well in clinical trials, and both have been widely credited with reducing disease, but concerns remain [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/covid-19-vaccine-generates-immune-structures-critical-for-lasting-immunity/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">172635</post-id>	</item>
	</channel>
</rss>
